Современные возможности лечения системной красной волчанки у детей (обзор литературы)
https://doi.org/10.14412/1996-7012-2024-4-99-105
Аннотация
Лечение системной красной волчанки с ювенильным началом (юСКВ) представляет собой сложную задачу с учетом разнообразия клинических проявлений и течения болезни, высокого риска повреждения органов. Необходимость создания отдельных принципов лечения юСКВ обоснована большей интенсификацией терапии за счет как используемых доз, так и сочетания большего числа разных препаратов у одного пациента. Однако на сегодня фундаментом лечения юСКВ является в основном экстраполяция данных, полученных в исследованиях взрослых пациентов.
В обзоре отражены современные представления о спектре лекарственных препаратов, применяемых при юСКВ, особое внимание уделено эффективности, безопасности, срокам назначения терапии, а также возможным перспективам ее оптимизации.
Ключевые слова
системная красная волчанка с ювенильным началом,
глюкокортикоиды,
генно-инженерная биологическая терапия,
детский возраст
При поддержке: Статья подготовлена в рамках фундаментальной темы №1021051302580-4.
Об авторах
М. И. Каледа
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
И. П. Никишина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Mina R, Brunner HI. Pediatric lupus – are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am. 2010 Feb;36(1):53-80, vii-viii. doi: 10.1016/j.rdc.2009.12.012.
2. Brunner HI, Vadhariya A, Dickson C, et al. Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Sci Med. 2023 Jul;10(2):e000817. doi: 10.1136/lupus-2022-000817.
3. Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):488-504. doi: 10.1016/j.berh.2018.02.001. Epub 2018 Mar 1.
4. Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017 Nov;76(11): 1788-1796. doi: 10.1136/annrheumdis-2016-210960. Epub 2017 Jun 19.
5. Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhoodonset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017 Dec;76(12):1965-1973. doi: 10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.
6. Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017 Oct;76(10):1637-1641. doi: 10.1136/annrheumdis-2016-211001. Epub 2017 May 4.
7. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun; 78(6):736-745. doi: 10.1136/annrheumdis2019-215089. Epub 2019 Mar 29.
8. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) Recommendations for the Management of Lupus Nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924. Epub 2020 Mar 27.
9. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2; 83(1):15-29. doi: 10.1136/ard-2023-224762.
10. Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019 Dec:209:108274. doi: 10.1016/j.clim.2019.108274. Epub 2019 Oct 31.
11. Deng J, Chalhoub NE, Sherwin CM, et al. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2019 Oct;49(2):251-259. doi: 10.1016/j.semarthrit.2019.03.010. Epub 2019 Mar 16.
12. Smith EMD, Egbivwie N, Jorgensen AL, et al. Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. Clin Immunol. 2022 Jun:239:109028. doi: 10.1016/j.clim.2022.109028. Epub 2022 May 2.
13. Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs. 2021 Jul; 23(4):331-347. doi: 10.1007/s40272-021-00457-z. Epub 2021 Jul 10.
14. Rygg M, Pistorio A, Ravelli A, et al; Paediatric Rheumatology International Trials Organisation (PRINTO). A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis. 2012 Apr;71(4):511-7. doi: 10.1136/annrheumdis-2011-200106. Epub 2011 Oct 13.
15. Kifer N, Sestan M, Frkovic M, et al. 2019 ACR/EULAR classification criteria and therapy in predicting organ damage accrual in patients with childhood-onset systemic lupus erythematosus: A retrospective study over the last 29 years. Lupus. 2022 Jun;31(7):828-836. doi: 10.1177/09612033221094707. Epub 2022 Apr 12.
16. Ferreira JC, Marques HH, Ferriani MP, et al. Herpes zoster infection in childhoodonset systemic lupus erythematosus patients: a large multicenter study. Lupus. 2016 Jun; 25(7):754-9. doi: 10.1177/0961203315627203. Epub 2016 Jan 27.
17. Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Irastorza G. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015 Oct;14(10):875-9. doi: 10.1016/j.autrev.2015.05.011. Epub 2015 Jun 1.
18. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109. doi: 10.1186/ar2764. Epub 2009 Jul 15.
19. Pan L, Liu J, Liu C, et al. Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy. Front Immunol. 2023 Aug 10:14: 1128754. doi: 10.3389/fimmu.2023.1128754. eCollection 2023.
20. Danza A, Borgia I, Narvaez JI, et al. Intravenous pulses of methylprednisolone to treat flares of immune-mediated diseases: How much, how long? Lupus. 2018 Jun;27(7): 1177-1184. doi: 10.1177/0961203318768888. Epub 2018 Apr 8.
21. Ruiz-Irastorza G., Garcia M., Espinosa G., et al. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort. Lupus Sci Med. 2016 Aug 2;3(1):e000153. doi: 10.1136/lupus-2016-000153. eCollection 2016.
22. Tarr T, Papp G, Nagy N, et al. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus. Clin Rheumatol. 2017 Feb; 36(2):327-333. doi: 10.1007/s10067-016-3492-6. Epub 2016 Nov 26.
23. Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011 Dec;20(14):1484-93. doi: 10.1177/0961203311418269. Epub 2011 Oct 5.
24. Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupusBordeaux cohorts. Autoimmun Rev. 2017 Aug; 16(8):826-832. doi: 10.1016/j.autrev.2017.05.017. Epub 2017 May 28.
25. Ruiz-Irastorza G, Ruiz-Estevez B, Lazaro E, et al. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmun Rev. 2019 Sep;18(9):102359. doi: 10.1016/j.autrev.2019.102359. Epub 2019 Jul 16.
26. Алексеева ЕИ, Дворяковская ТМ, Никишина ИП и др. Системная красная волчанка: клинические рекомендации. Часть 2. Вопросы современной педирии. 2018; 17(2):110-25.
27. Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14.
28. Massias JS, Smith EM, Al-Abadi E, et al. Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus. 2021 Apr;30(4):597-607. doi: 10.1177/0961203320984251. Epub 2021 Jan 7.
29. Zahr N, Urien S, Funck-Brentano C, et al. Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus. Pharmaceuticals (Basel). 2021 Mar 17;14(3): 273. doi: 10.3390/ph14030273.
30. Gheet FS, Dawoud HE, El-Shahaby WA, et al. Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. Eur J Pediatr. 2023 Apr;182(4): 1685-1695. doi: 10.1007/s00431-023-04837-0. Epub 2023 Feb 8.
31. Lim LSH, Pullenayegum E, Lim L, et al. From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1627-1635. doi: 10.1002/acr.23199. Epub 2017 Sep 26.
32. Kim JW, Kim YY, Lee H, et al. Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine. J Rheumatol. 2017 Nov; 44(11):1674-1679. doi: 10.3899/jrheum.170158. Epub 2017 Sep 1.
33. Каледа МИ, Никишина ИП. Современные международные рекомендации по диагностике и лечению системной красной волчанки с ювенильным дебютом. Научно-практическая ревматология. 2018;56(4):405-415.
34. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 Aug 21;135(4): 248-57. doi: 10.7326/0003-4819-135-4-200108210-00009.
35. Cannon LA, Wenderfer SE, Lewandowski LB, et al; CARRA Lupus Nephritis Workgroup. Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America. J Rheumatol. 2022 Jun;49(6):607-614. doi:10.3899/jrheum.210428. Epub 2022 Feb 15.
36. Smith E, Al-Abadi E, Armon K, et al. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus. 2019 Apr;28(5):613-620. doi: 10.1177/0961203319836712. Epub 2019 Mar 14.
37. Pennesi M, Benvenuto S. Lupus Nephritis in Children: Novel Perspectives. Medicina (Kaunas). 2023 Oct 16;59(10):1841. doi: 10.3390/medicina59101841.
38. Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al. Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis. 2017 Sep;70(3):324-336. doi: 10.1053/j.ajkd.2016.12.008. Epub 2017 Feb 21.
39. Mao Y, Yin L, Huang H, et al. Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. J Int Med Res. 2019 Jan;47(1):105-113. doi: 10.1177/0300060518796751. Epub 2018 Sep 12.
40. Chighizola CB, Ong VH, Meroni PL. The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review. Clin Rev Allergy Immunol. 2017 Jun;52(3):401-423. doi: 10.1007/s12016-016-8582-3.
41. Mok CC. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017 Jun;31(3):429-438. doi: 10.1016/j.berh.2017.09.010. Epub 2017 Oct 11.
42. Wen Y, Lu P, Lu H, Hu X. Successful treatment of subdural hemorrhage and retinal hemorrhage in childhood-onset systemic lupus erythematosus associated with thrombocytopenia: Case report. Medicine (Baltimore). 2021 Jan 15;100(2):e24231. doi: 10.1097/MD.0000000000024231.
43. Liu X, Peng Y, Cai S. The efficacy and safety of cyclosporine in children with systemic lupus erythematosus: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2023 Feb 22;102(8):e32314. doi: 10.1097/MD.0000000000032314.
44. Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40.
45. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005 Oct;52(10):3168-74. doi: 10.1002/art.21351.
46. Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and Efficacy of Rituximab in Childhood-onset Systemic Lupus Erythematosus and Other Rheumatic Diseases. J Rheumatol. 2015 Mar;42(3):541-6. doi: 10.3899/jrheum.140863. Epub 2015 Jan 15.
47. Watson L, Beresford MW, Maynes C, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015 Jan;24(1):10-7. doi: 10.1177/0961203314547793. Epub 2014 Aug 12.
48. Sawhney S, Agarwal M. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021 Oct;30(11):1829-1836. doi: 10.1177/09612033211034567. Epub 2021 Jul 27.
49. Алексеева ЕИ, Денисова РВ, Валиева СИ и др. Эффективность и безопасность ритуксимаба у детей с системной красной волчанкой: результаты ретроспективного исследования серии случаев. Вопросы современной педиатрии. 2016;15(5):497-504.
50. Каледа МИ, Никишина ИП, Николаева ЕВ и др. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214.
51. Cinar OK, Marlais M, Al Obaidi M, et al. Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience. Lupus. 2021 Mar;30(3):527-530. doi: 10.1177/0961203320981137. Epub 2020 Dec 16.
52. Lei L, Muhammad S, Al-Obaidi M, et al. Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C. Pediatr Rheumatol Online J. 2018 Sep 26; 16(1):61. doi: 10.1186/s12969-018-0278-1.
53. Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383.
54. Brunner HI, Abud-Mendoza C, Viola DO, et al; Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020 Oct;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101. Epub 2020 Jul 22.
55. Brunner HI, Abud-Mendoza C, Mori M, et al. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021 Sep;7(3):e001747. doi: 10.1136/rmdopen-2021-001747.
56. Dimelow R, Ji B, Struemper H. Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. Clin Pharmacol Drug Dev. 2021 Jun;10(6):622-633. doi: 10.1002/cpdd.889. Epub 2020 Nov 27.
57. Wang D, Shan C, Liu J, et al. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study. Front Immunol. 2022 Dec 14:13:1067721. doi: 10.3389/fimmu.2022.1067721. eCollection 2022.
58. Wang L, Liang X, Cao Z, et al. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from multicenter study. Rheumatology (Oxford). 2024 May 2;63(5): 1437-1446. doi: 10.1093/rheumatology/kead406.
59. Akbar L, Alsagheir R, Al-Mayouf SM. Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus. Eur J Rheumatol. 2020 Sep 8;7(4):184-189. doi: 10.5152/eurjrheum.2020.20087. Online ahead of print.
60. Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol. 2015 Dec; 42(12):2288-95. doi: 10.3899/jrheum.150470. Epub 2015 Nov 1.
61. Venturelli V, Isenberg DA. Targeted Therapy for SLE-What Works, What Doesn't, What's Next. J Clin Med. 2023 Apr 29;12(9): 3198. doi: 10.3390/jcm12093198.
62. Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov;74(11):2006-15. doi: 10.1136/annrheumdis-2013-205067. Epub 2014 Jun 20.
63. Zhang L, Cui JY, Zhang L. Clinical efficacy and safety of sirolimus in childhood-onset systemic lupus erythematosus in real world. Medicine (Baltimore). 2022 Nov 18; 101(46):e31551. doi: 10.1097/MD.0000000000031551.
64. Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial. Lupus. 2022 Jul;31(8):998-1006. doi: 10.1177/09612033221097812. Epub 2022 May 2.
65. Modica RF, Thatayatikom A, Bell-Brunson DH, Elder ME. Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases. Clin Rheumatol. 2023 Jul;42(7):1965-1979. doi: 10.1007/s10067-023-06559-y. Epub 2023 Mar 27.
66. Shaw KS, Rajeh A, Le T, et al. Anifrolumab for Adolescent Discoid Lupus Erythematosus. JAMA Netw Open. 2023 Oct 2;6(10): e2338200. doi: 10.1001/jamanetworkopen.2023.38200.
67. Pin A, Tesser A, Pastore S, et al. Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. Int J Mol Sci. 2020 Oct 20;21(20):7767. doi: 10.3390/ijms21207767.
68. Rossano M, Conti EA, Bocca P, et al. Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report. Front Immunol. 2023 Dec 6:14:1288675. doi: 10.3389/fimmu.2023.1288675. eCollection 2023.
69. Brunner HI, Martini A, Lovell DJ, Ruperto N. Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. Ann Rheum Dis. 2019 Feb;78(2):162-170. doi: 10.1136/annrheumdis-2018-213198. Epub 2018 Sep 19.
Рецензия
Для цитирования:
Каледа МИ, Никишина ИП. Современные возможности лечения системной красной волчанки у детей (обзор литературы). Современная ревматология. 2024;18(4):99-105. https://doi.org/10.14412/1996-7012-2024-4-99-105
For citation:
Kaleda MI, Nikishina IP. Modern treatment options for systemic lupus erythematosus in children (literature review). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2024;18(4):99-105. (In Russ.) https://doi.org/10.14412/1996-7012-2024-4-99-105
Просмотров:
615
Послать статью по эл. почте 